Hospital de Sant Pau

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus

  2025-524595-37-00· Phase 1· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Source

• Recruiting

  A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

  2026-525328-10-00· Phase 2· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· Source

• Not yet recruiting

  Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

  NCT07247786· Phase 2· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Not yet recruiting

  A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

  2026-525964-17-00· Phase 2· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· Source

• Not yet recruiting

  Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

  NCT07717099· Phase 2· Source

• Not yet recruiting

  iSGLT2 in permanent atrial fibrillation, heart failure with preserved ejection fraction and intermediate NT-proBNP values: randomized clinical trial

  2026-525968-18-00· Phase 4· Source

• Not yet recruiting

  Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma

  2026-525703-27-00· Phase 4· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· Source

• Recruiting

  Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

  2025-524793-42-00· Phase 2· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

  NCT07460986· Phase 1/2· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Source

• Recruiting

  A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes

  2025-524688-19-00· Phase 3· Source

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· Phase 2· Source

• Recruiting

  A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.

  2025-522076-85-00· Phase 2· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Source

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Source

• Not yet recruiting

  Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon

  NCT07650578· Source

• Not yet recruiting

  Optimizing the Use of Aspirin for the Prevention of Preeclampsia

  NCT07665853· Phase 3· Source

• Recruiting

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· Phase 2· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· Source

• Recruiting

  Grass Immunotherapy for Rhinitis and Asthma (GIRA)

  2025-521736-10-00· Phase 3· Source

• Recruiting

  Sevoflurane vs. Propofol for General Anesthesia in Patients With Acute Ischemic Stroke Treated With Endovascular Therapy

  NCT07902791· Phase 3· Source

• Recruiting

  Brain imaging to understand early changes in dementia related diseases

  2025-523284-37-00· Phase 2· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Source

• Recruiting

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  2025-525127-27-00· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer42 recruiting
• Prostate cancer20 recruiting
• Childhood cancers13 recruiting
• Bladder cancer12 recruiting
• Colorectal cancer12 recruiting
• Heart failure11 recruiting
• Sarcoma11 recruiting
• Acute myeloid leukemia10 recruiting
• Alzheimer disease9 recruiting
• Atrial fibrillation9 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• Lupus (SLE)9 recruiting
• Multiple myeloma9 recruiting
• Myasthenia gravis9 recruiting
• Stroke9 recruiting
• Fatty liver disease (MASLD/MASH)7 recruiting
• Parkinson disease7 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)6 recruiting
• Epilepsy6 recruiting
• Head and neck cancer6 recruiting
• Kidney cancer6 recruiting
• Systemic sclerosis (scleroderma)6 recruiting
• Coronary artery disease5 recruiting
• Depression5 recruiting
• Huntington's disease5 recruiting
• Pancreatic cancer5 recruiting
• Asthma4 recruiting
• Gastric and esophageal cancer4 recruiting
• Melanoma4 recruiting
• Obesity4 recruiting
• Psoriasis4 recruiting
• Rheumatoid arthritis4 recruiting
• Endometrial cancer3 recruiting
• HIV3 recruiting
• Metastatic breast cancer3 recruiting
• Ovarian cancer3 recruiting
• Sjögren's disease3 recruiting
• Type 1 diabetes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Cervical cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Liver and biliary tract cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Schizophrenia2 recruiting
• Sickle cell disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Amyloidosis1 recruiting
• Ankylosing spondylitis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• COPD1 recruiting
• Diabetic eye disease1 recruiting
• Endometriosis1 recruiting
• Frontotemporal dementia1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• Macular degeneration1 recruiting
• Migraine1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Psoriatic arthritis1 recruiting
• Thalassaemia1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment

  2025-522235-34-00· Phase 4· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

  NCT07234942· Phase 1· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Source

• Completed

  C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05896163· Phase 1/2· Source

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· Source

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Source

• Completed

  An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

  2024-517061-16-01· Phase 2· Source

• Completed

  A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

  2023-505908-28-00· Phase 1· Source

• Completed

  Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

  2023-509257-31-00· Phase 1· Source

• Completed

  A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer

  2024-514048-98-00· Phase 3· Source

• Active, not recruiting

  Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

  NCT06219317· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Source

• Completed

  Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers.

  2024-514748-10-00· Phase 1· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Active, not recruiting

  Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

  NCT06359002· Phase 1· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Source

• Completed

  Compression Therapy of the Lower Limbs in Patients With Decompensated Heart Failure

  NCT06418932· Source

• Completed

  A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

  2023-506881-30-00· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Source

• Completed

  A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

  NCT05813288· Phase 3· Source

• Completed

  Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

  NCT06119217· Phase 2· Source

• Completed

  A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to test the effect of brigatinib after standard chemotherapy and radiation therapy is completed.

  NCT05718297· Phase 2· Source

• Completed

  A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia

  2023-506197-12-00· Phase 2· Source

• Completed

  VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

  NCT06214052· Phase 2· Source

• Completed

  A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients

  2023-505241-10-00· Phase 2· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Source

• Completed

  Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.

  2022-502413-29-00· Phase 2· Source

• Completed

  RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).

  2023-509075-17-00· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).

  NCT05797792· Phase 3· Source

• Completed

  CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL)

  2023-504262-32-01· Phase 3· Source

• Terminated

  IMM60 and Pembrolizumab in Melanoma and NSCLC

  NCT05709821· Phase 1/2· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Source

• Completed

  A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

  NCT06073119· Phase 2· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· Source

• Completed

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· Phase 2· Source

Trial sites

• 7240050 - Hospital de la Santa Creu i Sant Pau1 trial
• Hopital Sant Pau1 trial
• Hosp. de La Santa Creu I Sant Pau9 trials
• Hospital de la Santa Creu i de Sant Pau4 trials
• Hospital de la Santa Creu i Sant Pau709 trials
• Hospital de la Santa Creu i Sant Pau Barcelona1 trial
• Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 080411 trial
• Hospital de la Santa Creu i Sant Pau - Dept of Oncology2 trials
• Hospital de La Santa Creu i Sant Pau - Dermatologia0 trials
• Hospital de la Santa Creu i Sant Pau /ID# 2796420 trials
• Hospital de la Santa Creu i Sant Pau Servicio de Dermatologia0 trials
• HOSPITAL DE LA SANTA CREU I SANT PAU - Servicio de Hematología1 trial
• Hospital de la Santa Creu i Sant Pau (Site 0385)0 trials
• Hospital de la Santa Creu I Sant Pau Site #13040 trials
• Hospital de la Santa Creu i Sant Pau (Site 1807)0 trials
• Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento1 trial
• Hospital de la Santa Creu i Sant Pau, Unitat de Diabetis, Servei d'Endocrinologia i Nutrició, Universitat Autònoma de Barcelona0 trials
• Hospital del la Santa Creu i Sant Pau1 trial
• Hospital de Santa Creu I Sant Pau1 trial
• Hospital de Sant Pau5 trials
• Hospital de Sant Pau i de la Santa Creu1 trial
• Hospital De Sant Pau I La Santa Creu1 trial
• Hospital Santa Creu i Sant Pau14 trials
• Hospital Santa Creu i Sant Pau /ID# 1142-05351 trial
• Hospital Santa Creu i Sant Pau /ID# 1249631 trial
• Hospital Santa Creu i Sant Pau /ID# 1531930 trials
• Hospital Santa Creu i Sant Pau /ID# 1541251 trial
• Hospital Santa Creu i Sant Pau /ID# 2013250 trials
• Hospital Santa Creu i Sant Pau /ID# 2147140 trials
• Hospital Santa Creu i Sant Pau /ID# 2154291 trial
• Hospital Santa Creu i Sant Pau /ID# 2258130 trials
• Hospital Santa Creu i Sant Pau /ID# 2298590 trials
• Hospital Santa Creu i Sant Pau /ID# 2318211 trial
• Hospital Santa Creu i Sant Pau /ID# 2385011 trial
• Hospital Santa Creu i Sant Pau /ID# 2485111 trial
• Hospital Santa Creu i Sant Pau /ID# 2572941 trial
• Hospital Santa Creu i Sant Pau /ID# 2604980 trials
• Hospital Santa Creu i Sant Pau /ID# 2626370 trials
• Hospital Santa Creu i Sant Pau /ID# 2713110 trials
• Hospital Santa Creu i Sant Pau /ID# 2763191 trial
• Hospital Santa Creu i Sant Pau (Site 0241)1 trial
• Hospital Santa Creu i Sant Pau (Site 1501)1 trial
• Hospital Santa Creu i Sant Pau (Site 4102)0 trials
• Hospital Sant Pau4 trials
• Hospital Sant Pau Barcelona0 trials
• Hospital Sant Pau i la Santa Creu (Site 0905)0 trials
• Neurology (Memory Unit) - Hospital de la Santa Creu i Sant Pau1 trial
• Sant Pau Hospital0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease260 works · 29 trials
• Psoriasis78 works · 19 trials
• Sarcoma59 works · 23 trials
• Crohn's disease23 works · 1 trials
• Huntington's disease20 works · 13 trials
• Myasthenia gravis19 works · 15 trials
• Lewy body dementia14 works · 0 trials
• Frontotemporal dementia14 works · 2 trials
• Systemic sclerosis (scleroderma)13 works · 17 trials
• Pompe disease9 works · 1 trials
• Duchenne muscular dystrophy7 works · 0 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 works · 10 trials